# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ir-CPI in Healthy Male Subjects

> **NCT04653766** · PHASE1 · COMPLETED · sponsor: **Bioxodes S.A.** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ir-CPI - Dose 1
- **DRUG:** Ir-CPI - Dose 2
- **DRUG:** Ir-CPI - Dose 3
- **DRUG:** Ir-CPI - Dose 4
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04653766
- **Lead sponsor:** Bioxodes S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-12
- **Primary completion:** 2020-07-18
- **Final completion:** 2023-01-04
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04653766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04653766, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ir-CPI in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04653766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*